Sientra Inc (NASDAQ:SIEN) – Analysts at Dougherty & Co issued their Q1 2019 EPS estimates for Sientra in a note issued to investors on Wednesday, March 13th. Dougherty & Co analyst K. Bauser anticipates that the medical instruments supplier will post earnings of ($0.81) per share for the quarter. Dougherty & Co currently has a “Buy” rating and a $27.00 target price on the stock. Dougherty & Co also issued estimates for Sientra’s FY2019 earnings at ($2.98) EPS and FY2020 earnings at ($2.32) EPS.
A number of other equities research analysts have also issued reports on the stock. Wells Fargo & Co initiated coverage on shares of Sientra in a report on Thursday. They set a “market perform” rating and a $9.00 target price on the stock. ValuEngine lowered shares of Sientra from a “buy” rating to a “hold” rating in a report on Thursday. Stifel Nicolaus reduced their price objective on shares of Sientra from $19.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday. Leerink Swann reduced their price objective on shares of Sientra from $22.00 to $18.00 in a report on Wednesday. Finally, William Blair lowered shares of Sientra from an “outperform” rating to a “market perform” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $19.50.
Sientra stock opened at $8.34 on Friday. The company has a market cap of $325.46 million, a price-to-earnings ratio of -2.57 and a beta of -0.04. Sientra has a 52-week low of $7.74 and a 52-week high of $26.79. The company has a current ratio of 2.77, a quick ratio of 2.34 and a debt-to-equity ratio of 0.36.
Sientra (NASDAQ:SIEN) last released its earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.19). The business had revenue of $19.02 million for the quarter, compared to analyst estimates of $18.87 million. Sientra had a negative return on equity of 123.50% and a negative net margin of 121.28%.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Sientra by 10.0% in the fourth quarter. Geode Capital Management LLC now owns 254,747 shares of the medical instruments supplier’s stock valued at $3,237,000 after acquiring an additional 23,117 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Sientra in the fourth quarter valued at about $135,000. HRT Financial LLC purchased a new stake in shares of Sientra in the fourth quarter valued at about $157,000. Millennium Management LLC boosted its holdings in shares of Sientra by 117.6% in the fourth quarter. Millennium Management LLC now owns 966,106 shares of the medical instruments supplier’s stock valued at $12,279,000 after acquiring an additional 522,153 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its holdings in shares of Sientra by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock valued at $104,000 after acquiring an additional 6,397 shares in the last quarter. Institutional investors and hedge funds own 92.79% of the company’s stock.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Article: What causes a recession?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.